Reports Q3 revenue $3.363M, consensus $3.7M. "We continued to make meaningful progress across the entirety of our pipeline during the third quarter and look forward to providing an update on our Phase 1 clinical trial by the end of this year. We plan to commence clinical development for the solid tumor program with multiple TCRs next year," said David P. Southwell, President and Chief Executive Officer. "On the financing side, we are pleased to have secured a debt facility for up to $60 million with K2 HealthVentures during the third quarter. The initial $30 million that we drew at the close provides TScan with a cash runway into the second quarter of 2024."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TCRX:
- TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
- TScan Therapeutics Announces Upcoming Virtual Investor Event
- TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
- TScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting
- TScan Therapeutics to Participate in Upcoming Investor Conferences